ZyCoV-D
From EverybodyWiki Bios & Wiki
| Vaccine description | |
|---|---|
| Target disease | COVID-19 |
| Type | DNA vaccination |
| Clinical data | |
| Routes of administration | Intramuscular |
| Identifiers | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}} |
| Part of a series on the |
| COVID-19 pandemic |
|---|
|
|
|
International response |
|
Medical response |
|
ZyCoV-D is a COVID-19 vaccine candidate developed by Cadila Healthcare.
Development
In July 2020, the company received permission to conduct human trials of the developmental COVID-19 vaccine named ZyCoV-D, from the Drugs Controller General of India (DCGI), Government of India.[1][2][3]
Cadila is also among the several Indian pharmaceutical companies that received licensing agreements from the Gilead Sciences to produce remdesivir[4]
References
- ↑ "Potential COVID-19 vaccine by Zydus Cadila gets DCGI nod for human clinical trials". The Hindu. 3 July 2020.
- ↑ "Zydus Cadila begins human clinical trials of COVID-19 vaccine candidate - ET HealthWorld". ETHealthworld.com.
- ↑ "Zydus Cadila's COVID-19 Vaccine Candidate Found Safe in Early-Stage Human Trial". The New York Times. 5 August 2020.
- ↑ Umarji, Vinay (12 June 2020). "Gilead finds fourth partner for manufacture of Remdesivir in Zydus Cadila". Business Standard India.
External links
This article "ZyCoV-D" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:ZyCoV-D. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
|
This page exists already on Wikipedia. |
